Image

Clinical Feasibility and Evaluation Study of POINT-GUARD Embolic Protection Device During TAVR (GUARDIAN)

Clinical Feasibility and Evaluation Study of POINT-GUARD Embolic Protection Device During TAVR (GUARDIAN)

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The purpose of this study is to assess the feasibility and safety of the Transverse Medical, Inc. Point-Guard device. This feasibility study is a limited clinical investigation of the Point-Guard device. The study will be conducted to evaluate the device design concept with respect to clinical safety and device functionality.

Description

This is a prospective, single-arm, multi-center, open study to assess the clinical performance and safety of the Point-Guard CEPD during a TAVR procedure.

Eligibility

Inclusion Criteria:

  1. The patient is ≥18 years of age;
  2. The patient meets indications for Transcatheter Aortic Valve Replacement (TAVR);
  3. The patient is willing to comply with protocol-specified follow-up evaluations;
  4. The patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent, approved by the appropriate Institutional Review Board or Ethics Committee.

Exclusion Criteria:

  1. TAVR conducted via other than transfemoral access (subclavian, axillar, transapical, transaortic, carotid or transcaval).
  2. Anatomy that precludes safe delivery and retrieval of the investigational device.
  3. Current or planned treatment with any investigational drug or investigational device during the study enrollment or follow-up period.
  4. Cardiovascular surgical or interventional procedure 10 days prior or planned during the TAVR procedure or during the 30-day study follow-up.
  5. Patients with uncontrolled bleeding disorders.
  6. Patients who are pregnant, as confirmed by a positive pregnancy test.

General Exclusion Criteria

  1. TAVR conducted via other than transfemoral access (subclavian, axillar, transapical, transaortic, carotid or transcaval).
  2. Anatomy that precludes safe delivery and retrieval of the investigational device.
  3. Current or planned treatment with any investigational drug or investigational device during the study enrollment or follow-up period.
  4. Cardiovascular surgical or interventional procedure 10 days prior or planned during the TAVR procedure or during the 30-day study follow-up.
  5. Patients with uncontrolled bleeding disorders.
  6. Patients who are pregnant, as confirmed by a positive pregnancy test.

Magnetic resonance imaging exclusion criteria:

  1. Body Mass Index (BMI) and/or total body weight precluding imaging in scanner.
  2. Contraindications to MRI (subjects with any implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure).
  3. High risk of complete AV block after TAVR, with the need of permanent pacemaker (e.g., subjects with pre-existing bifascicular block or complete right bundle branch block plus any degree of AV block).
  4. Existing or planned implantation of a pacemaker or defibrillator implantation within the first 3 days after TAVR.
  5. Claustrophobia precluding MRI scanning.

Study details
    Transcatheter Aortic Valve Implantation (TAVI)
    Aortic Valve Stenosis
    Transcatheter Aortic Valve Replacement

NCT06962371

Transverse Medical, Inc.

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.